- Home
- VNRX vs QNCX Comparison
VNRX vs QNCX Comparison
Compare VNRX & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNRX | QNCX |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 19.9M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VNRX | QNCX |
|---|---|---|
| Price | $2.73 | $1.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $1.67 | N/A |
| AVG Volume (30 Days) | 276.1K | ★ 1.4M |
| Earning Date | 05-12-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.00 | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | ★ $1,727,384.00 | N/A |
| Revenue This Year | $355.66 | N/A |
| Revenue Next Year | $849.08 | N/A |
| P/E Ratio | ★ N/A | $0.41 |
| Revenue Growth | ★ 40.04 | N/A |
| 52 Week Low | $0.13 | $0.08 |
| 52 Week High | $3.26 | $4.55 |
Technical Indicators
Market Signals| Indicator | VNRX | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 65.78 | 55.84 |
| Support Level | $0.22 | $1.17 |
| Resistance Level | $2.89 | $1.45 |
| Average True Range (ATR) | 0.29 | 0.12 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 64.18 | 70.54 |
Price Performance
Historical ComparisonAbout VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.